TIAA CREF Investment Management LLC Purchases 36,674 Shares of Selecta Biosciences, Inc. (SELB)

TIAA CREF Investment Management LLC raised its position in shares of Selecta Biosciences, Inc. (NASDAQ:SELB) by 714.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 41,807 shares of the company’s stock after purchasing an additional 36,674 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Selecta Biosciences were worth $830,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in SELB. Bank of New York Mellon Corp bought a new stake in shares of Selecta Biosciences during the 1st quarter valued at about $211,000. Rhumbline Advisers purchased a new position in shares of Selecta Biosciences during the 2nd quarter valued at about $239,000. Trexquant Investment LP purchased a new position in shares of Selecta Biosciences during the 2nd quarter valued at about $334,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Selecta Biosciences during the 2nd quarter valued at about $392,000. Finally, Teachers Advisors LLC lifted its position in shares of Selecta Biosciences by 294.2% during the 2nd quarter. Teachers Advisors LLC now owns 21,292 shares of the company’s stock valued at $423,000 after buying an additional 15,890 shares in the last quarter. Institutional investors and hedge funds own 53.03% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/11/13/tiaa-cref-investment-management-llc-purchases-36674-shares-of-selecta-biosciences-inc-selb.html.

In other news, CFO David Siewers sold 16,424 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total transaction of $328,480.00. Following the sale, the chief financial officer now directly owns 2,194 shares of the company’s stock, valued at approximately $43,880. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amir Nashat sold 42,610 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $20.03, for a total value of $853,478.30. The disclosure for this sale can be found here. Insiders have sold a total of 355,658 shares of company stock worth $6,955,732 over the last ninety days. Insiders own 41.90% of the company’s stock.

Shares of Selecta Biosciences, Inc. (SELB) opened at $9.03 on Monday. Selecta Biosciences, Inc. has a twelve month low of $8.70 and a twelve month high of $28.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings data on Friday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.01. The business had revenue of $0.03 million for the quarter. Selecta Biosciences had a negative return on equity of 100.06% and a negative net margin of 1,918.59%. research analysts anticipate that Selecta Biosciences, Inc. will post -2.25 earnings per share for the current year.

A number of research analysts have recently weighed in on SELB shares. Zacks Investment Research raised Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Saturday. Canaccord Genuity set a $25.00 price objective on Selecta Biosciences and gave the company a “buy” rating in a research report on Wednesday, July 26th. ValuEngine cut Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Finally, UBS AG cut Selecta Biosciences from a “buy” rating to a “neutral” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $25.20.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences, Inc. (NASDAQ:SELB).

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply